Idiopathic Pulmonary Fibrosis is a rare lung condition in which scar tissue slowly builds up in the lungs, making it harder to breathe over time. The study is testing an oral tablet called PIPE-791 and comparing it with a placebo to see if the medicine can slow the loss of lung function.
The purpose of the study is to find out whether PIPE-791 can preserve breathing ability better than the placebo. Participants will take the study medication or placebo every day for about six months, with regular visits to check health, report any side effects, and undergo simple breathing tests. One of the key breathing tests measures forced vital capacity (FVC), which is the amount of air a person can push out of the lungs after taking a deep breath; this helps doctors see how the lungs are working. At selected visits, a special detailed X‑ray scan called HRCT will be used to look at the amount of scarring in the lungs. The study follows participants for the full treatment period to monitor safety and how well the drug works.
Belgium 
France 
Germany 
Greece 
